Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2022 Aug 23;36(10):2544–2547. doi: 10.1038/s41375-022-01681-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Fig. 1 — a Survival probabilities of CML patients in CP with high-risk ACA emerging after diagnosis (n = 66) compared to 32 patients with low-risk ACA occurring either at or after diagnosis synchronized for the time to emergence of ACA. b Survival probabilities of patients in CP with high-risk ACA occurring at diagnosis (n = 25) compared to the 32 patients with low-risk ACA occurring either at or after diagnosis synchronized for the time to emergence of ACA. Survival with high-risk ACA occuring at versus emerging after diagnosis is not significantly different (p = 0.5). c Survival probabilities of CML patients in CP with high-risk ACA compared with a matched cohort of patients without high-risk ACA by resampling [9], p = 0.024, median hazard ratio 2.15, d with confidence intervals. e Survival probabilities of patients in CP with low-risk ACA compared with a matched cohort of patients with no ACA by resampling [9], p = 0.204, median hazard ratio 2.46, f with confidence intervals. CML chronic myeloid leukemia, ACA additional chromosomal abnormalities, pts patients, CP chronic phase.